Singapore-based health technology company Respiree has expanded its Series A funding round with new participation from ARKRAY & PARTNERS Pte. Ltd. and Bizedge Capital. The company develops artificial intelligence and machine learning platforms that manage disease progression across the healthcare continuum. The additional funding will support the growth of its global commercial team and its expanding presence in the United States.
Expanded Series A Syndicate
Respiree announced that ARKRAY & PARTNERS Pte. Ltd. and Bizedge Capital have joined its Series A syndicate. The round is led by We Venture Capital and ClavystBio, with previously announced participation from Adaptive Capital Partners, Greenwillow Capital Management, Seeds Capital, and One Six 8 Ventures. The company has not disclosed the total amount raised in this expanded financing, but the new participants broaden its international investor base.
Use of Funds and U.S. Expansion
Respiree intends to use the new capital to continue growing its global commercial team and to accelerate its expansion in the United States. The company is building its U.S. presence from Houston at the Texas Medical Center Innovation. This location supports the company's broader international growth across the United States, Australia, and the Asia-Pacific region.
Technology and Regulatory Clearances
Respiree's 1Bio platform uses electronic health record data alongside proprietary sensors that are patented in the United States and cleared by the U.S. Food and Drug Administration. The platform is designed to longitudinally measure and track disease progression over time. Respiree currently operates in the United States, Australia, and the Asia-Pacific region and holds CE marking, TGA clearance in Australia, and FDA 510(k) clearance.
Leadership Commentary
Founder and Chief Executive Officer Dr. Gurpreet Singh said the company continues to be encouraged by interest from leading investors around the world. He noted that these investors bring strategic perspective and experience in solving health inefficiencies in specific markets. Singh added that the new participation from AAP and Bizedge Capital enhances Respiree's ability to grow and invest globally.
Investor Background
AAP is an affiliate of ARKRAY Inc., based in Kyoto, Japan, and operates the ARKRAY 4U corporate venture capital business. It has an investment allocation of JPY 10 billion and primarily targets medical and healthcare startups across Asia. Bizedge Capital is a private investment firm focused on transformative companies in semiconductors, artificial intelligence, robotics, automation, and related fields.
Market Position
Respiree is headquartered in Singapore and develops artificial intelligence and machine learning based healthcare technology. Its 1Bio platform combines electronic health record data with proprietary sensors to provide longitudinal tracking of disease progression. The company's technology is currently available in the United States, Australia, and Asia-Pacific, with regulatory clearances supporting its commercial deployments.
What Happens Next
Respiree will focus on expanding its global commercial team while strengthening its presence in the U.S. market. The company plans to continue developing and deploying its AI-based disease progression management platform across its existing international markets. Its Houston base at the Texas Medical Center Innovation will remain central to this expansion strategy.
With the expanded Series A syndicate, Respiree is positioned to strengthen its commercial infrastructure and accelerate its United States growth from Houston. The company will also continue deploying its AI-based disease progression management platform across existing international markets. The undisclosed funding extension underscores investor confidence in Respiree's regulatory clearances and clinical validation.